H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Translate Bio Inc (TBIO) today and set a price target of $21. The company’s shares closed on Friday at $9.54.
Fein commented:
“We remind investors that the company has importantly highlighted the MAD portion of the MRT5005 trial as representative of the first time multiple doses of an mRNA therapeutic have been utilized in patients for treating a genetic disease. This portion of the Phase 1/2 trial can also provide greater insight into MRT5005’s safety profile in the CF patient population. MRT5005 is the company’s mRNA therapeutic designed to treat CF patients using targeted liposome encapsulated nanoparticles delivered by nebulization. We continue to believe in the platform value of targeting protein or gene dysfunction through an mRNA focus, as it stands to directly address the functional protein deficiencies underlying the disease state.”
According to TipRanks.com, Fein is a 4-star analyst with an average return of 3.9% and a 43.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
Translate Bio Inc has an analyst consensus of Moderate Buy, with a price target consensus of $21.
See today’s analyst top recommended stocks >>
The company has a one-year high of $16.60 and a one-year low of $4.81. Currently, Translate Bio Inc has an average volume of 224.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency.
